查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835258

止血劑和組織密封劑市場（按產品類型、材料類型、應用和最終用戶）—2025-2032 年全球預測

Hemostats & Tissue Sealants Market by Product Type, Material Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年止血劑和組織密封劑市場將成長 178 億美元，複合年成長率為 12.67%。

主要市場統計數據
基準年2024年 68.5億美元
預計2025年 76.9億美元
預測年份：2032年 178億美元
複合年成長率（%） 12.67%

對止血和組織密封劑領域的清晰、權威的介紹，說明臨床和監管方面以及產品採用的促進因素

止血和組織封閉劑領域正發展成為一個影響深遠的細分領域，融合了外科創新、手術全期安全和注重成本的醫療系統管理。臨床團隊正在尋求能夠簡化止血流程、縮短手術時間並減少術後併發症的輔助產品，涵蓋心血管外科、胃腸開放性手術。

同時，監管審查和付款人的期望正在影響製造商如何優先考慮證據生成和價值展示。這種環境鼓勵研發團隊、臨床專家和衛生經濟學專家之間的多學科合作，以檢驗主要療效終點之外的真實世界結果。因此，產品開發的重點正從止血和密封性能轉向包括操作特性、儲存穩定性以及與輔助器具和植入的兼容性。

在這種環境下，相關人員必須在技術創新與營運現實之間取得平衡。醫院和門診醫療機構會根據產品的實施難易度、員工訓練要求和供應鏈可靠性來評估產品，而臨床醫生則會權衡複雜出血情況下的臨床優勢。本入門框架將探討隨之而來的結構性變化、關稅影響、市場區隔考量、區域動態、競爭行動，並為產業領導者提供實際的建議，幫助他們應對當前的市場格局。

外科趨勢、材料創新和價值主導採購如何重塑產品開發路徑和臨床應用動態

在外科手術、材料科學和醫療體系經濟學趨勢的推動下，止血劑和組織封閉劑領域正在經歷重大變化。微創手術和機器人手術不斷擴展到複雜的適應症，對在狹窄工作空間以及抽吸和沖洗條件下可靠工作的製劑的需求不斷增加。因此，製造商正在投資開發下一代可流動和可活化的止血劑，以增強黏附性和血塊穩定性，同時保持生物相容性。

材料創新也是變革的關鍵軸心。聚合物工程和生技藥品加工技術的進步使得模擬纖維蛋白基質的合成密封劑成為可能，同時延長了保存期限並實現了性能標準化。同時，膠原蛋白基支架和複合材料結構也得到了改進，這些結構針對特定的組織界面，從血管吻合口到內臟漿膜表面。由此，產品種類更加豐富，可以根據外科醫師的偏好和特定手術的止血挑戰進行客製化。

隨著採購方式的演變，市場動態也正在改變。醫療系統擴大在綜合護理路徑和基本契約價值的合約框架內評估產品，並要求供應商提供相關指標的證據，例如降低輸血率、減少因出血而再次手術以及縮短住院時間。與這些商業性力量相輔相成的是，從庫存管理分析到術中決策支援等數位醫療整合，為產品差異化和展示可衡量的系統級效益提供了新的途徑。總而言之，這些轉型變革正在重塑整個生態系統的產品藍圖、臨床應用軌跡和競爭定位。

評估2025年美國關稅調整對供應鏈、籌資策略和定價動態的多面向影響

美國宣布的2025年關稅環境將對止血鉗和組織封閉劑生態系統的相關人員產生多層次的成本和營運影響。依賴全球原料採購或擁有跨境生產基地的製造商可能面臨更高的到岸成本，這將對其定價策略和利潤結構造成壓力。這些壓力可能會促使其採取近岸外包措施、重新談判供應商契約，並重新考慮組件標準化，以降低關稅風險。

醫院和門診護理機構可能會因供應鏈波動而受到間接影響，這可能會影響處方箋和供應商整合策略。為此，採購團隊可能會優先考慮多源資格、增加安全庫存以及延長關鍵產品的前置作業時間。對於規模較小的供應商和新進業者而言，與關稅相關的成本上漲可能會增加規模壁壘，影響合作策略，並促使其與能夠吸收短期成本波動的大型公司達成合併和分銷協議。

在監管和報銷方面，關稅格局與更廣泛的成本控制措施相互交織，鼓勵製造商根據臨床結果和醫療保健總成本製定更強力的價值提案。應對關稅的策略措施可能包括：改革配方以納入國產原料；重新設計包裝以降低進口關稅；或尋求更深入的臨床證據，以支持溢價（當療效顯著改善時）。整體而言，關稅變動的累積影響將取決於各相關人員調整供應鏈設計、合約實務和實證價值溝通的能力。

將產品類型、材料類別、臨床應用和最終用戶環境與策略商業化需求連結起來的詳細細分見解

細緻地了解細分市場對於制定適用於不同臨床和商業子市場的產品策略和商業化計劃至關重要。依產品類型分類，有止血劑和組織封閉劑，其中止血劑分為活性止血劑、流動止血劑和機械止血劑，組織密封膠分為纖維蛋白膠封閉劑和合成封閉劑。此產品分類會影響臨床醫生如何根據出血嚴重程度、解剖入路以及對生物材料和人工材料的性能偏好來選擇輔助治療方案。

材料類型提供了一個正交的細分軸，影響材料的來源、監管途徑和臨床風險認知。天然材料包括牛和人源，需要考慮供體的差異性、無菌性和免疫抗原性。合成材料包括基於膠原蛋白和聚合物的結構，可以實現批次一致性和客製化的分解特性，但需要嚴格的生物相容性驗證才能獲得臨床醫生的信任。

非手術應用包括診斷程序和小傷口覆蓋，而手術應用包括心血管、胃腸道和一般外科手術。臨床應用決定了關鍵的產品需求，例如動態流動條件下的黏附性、吻合口的抗張強度以及與電外科設備的兼容性。最後，終端使用者細分（門診手術中心、診所和醫院）會影響分銷管道偏好、庫存狀況和採購權限。在製定上市計劃和上市後監測策略時，必須考慮所有這些因素。

美洲、歐洲、中東和非洲地區以及亞太地區的臨床實踐、監管差異和製造能力動態將如何影響差異化策略

區域動態在決定止血劑和組織封閉劑的研究重點、監管流程和商業策略方面發揮關鍵作用。在美洲，先進的醫療基礎設施和活躍的外科手術量，對成熟的生物止血劑和創新的合成封閉劑都產生了強烈的臨床需求。該地區的相關人員通常強調可靠的臨床證據和與綜合護理模式的整合，這影響供應商如何表達價值並參與報銷。

在歐洲、中東和非洲，管理體制差異和採購慣例的多樣性造就了複雜的商業環境。歐洲市場可能青睞擁有豐富療效比較數據和可靠供應的產品，而該地區的新興市場則更重視成本效益和分銷便利性。這種多樣性要求企業制定靈活的打入市場策略，既尊重當地監管機構的期望，也要利用集中化的臨床數據進行跨國核准。

亞太地區正經歷微創技術的快速普及，國內製造能力的投資也不斷成長。本地創新生態系統和不斷發展的法律規範日益支持本地研發製劑的臨床試驗和商業化。因此，能夠展示可擴展生產能力、本地化監管策略以及與區域臨床領導者建立夥伴關係的供應商將佔據有利地位，抓住該地區手術量成長和產能擴張帶來的機會。

產業競爭與合作動態揭示了現有企業、專家和創新者如何塑造供應、證據和商業化策略

競爭格局的特點是成熟的手術器械製造商、專業的生技藥品公司以及專注於材料創新和新型交付形式的敏捷新興企業的混合，而新參與企業通常專注於單一適應症差異化或專有聚合物化學，以解決未滿足的處理或性能差距。

夥伴關係和授權協議是擴大銷售和整合互補技術的常見機制，使公司能夠將臨床可靠性與專業的製造技術相結合。同時，受託製造廠商和特殊材料供應商在確保品質、法規合規性和產能擴充性發揮著至關重要的作用，尤其對於需要生物輸入或複雜聚合物合成的產品而言。

各公司的策略重點包括：透過針對性的臨床研究拓展適應症，最佳化微創平台的產品系列，以及展現健康經濟價值，以引起醫院採購委員會的共鳴。能夠將研發投資與明確的臨床終點相結合，並展示系統級經濟效益的公司，將能夠更有效地影響處方決策和外科實踐模式。

為領導者提供切實可行的建議，以協調臨床證據、彈性供應鏈和價值主導的商業策略，實現永續採用

為了確保持續應用，產業領導者應採取多層次的方法，協調臨床開發、供應鏈韌性和商業性參與。首先，投資於將產品性能與有意義的手術全期結果聯繫起來的可靠臨床證據至關重要。實用性試驗和真實世界資料收集應納入產品上市和上市後計劃，以支持不同醫療機構的採用。

其次，企業應重新考慮其供應鏈架構，以降低關稅風險和物流中斷。相關策略包括確保替代原料來源、在關鍵地區尋求本地製造夥伴關係以及重新設計包裝以降低跨境關稅。除上述措施外，還應與採購團隊保持透明溝通，以便在定價和供應調整期間建立信任。

第三，商業化應強調臨床醫生培訓、清晰的操作指南以及與微創工作流程和輔助設備的兼容性。為門診手術中心、診所和醫院量身定做的價值提案，有助於滿足其獨特的購買行為和臨床工作流程。最後，積極與付款人和醫療系統價值負責人溝通，提供全面的療效和成本說明，將有助於在基於價值的醫療討論和捆綁支付安排中佔據有利地位。

一種透明、多方法的調查方法，結合臨床醫生的見解、調查和供應鏈分析來提供策略建議

本分析背後的調查方法結合了定性和定量分析，以確保觀點的全面性和可操作性。主要研究包括對心血管外科、胃腸病學和一般外科的臨床專家以及醫院、門診手術中心和診所的採購負責人進行結構化訪談。這些討論重點關注了每類止血劑和封閉劑的實際臨床表現、操作偏好、採購標準以及採用障礙。

二次分析結合了同行評審的臨床文獻、監管指南文件、產品標籤和生產標準，以檢驗材料性能聲明和監管途徑。我們透過貿易流量分析、投入成本審查以及諮詢行業採購專家，進行了供應鏈圖譜繪製和關稅影響評估，以確定潛在的營運影響和緩解措施。

對數據來源進行三角測量，以支持研究結果並明確戰略意義。調查方法框架優先考慮歸因的透明度、分析程序的可重複性以及對區域監管差異的敏感度。我們識別了研究的局限性和數據缺口，以指南未來的研究重點，並在必要時有針對性地收集原始數據。

簡潔的結論整合了臨床需求、供應鏈彈性和策略證據需求，這些將決定長期採用和價值實現

總而言之，止血和組織密封膠產業正處於戰略曲折點，臨床需求、材料科學進步和經濟壓力交織在一起。在這種環境下取得成功需要一種整合策略，將差異化的產品性能與下游臨床和營運效益的有力證據相結合。投資於切實可行的臨床項目、靈活的生產和採購模式以及有針對性的商業化方法的相關人員，將最有能力在多元化的醫療環境中影響該技術的採用。

關稅主導的成本動態和不斷變化的採購行為凸顯了供應鏈設計的敏捷性和價值溝通的清晰度的重要性。同時，由於監管預期和基礎設施成熟度存在地區差異，本地化的監管和商業化方法將保持競爭優勢。最終，能夠將創新與醫院和患者層面的顯著成果相結合的公司將塑造醫療保健的標準，並在這個不斷發展的領域中抓住最具永續的機會。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 合成和混合聚合物密封劑在先進外科手術的應用日益廣泛
  • 開發富含生長因子的生物來源止血粉，促進創傷治療
  • 微創機器人手術的擴展正在推動腹腔鏡手術對精密組織密封膠的需求
  • 生物相容性和止血效果得到改善的明膠基止血劑正在獲得市場支持
  • 一種創新的噴霧止血劑，可在創傷和緊急手術環境中快速應用
  • 加大對心血管外科手術靶向止血的照護現場纖維蛋白原濃縮物的投入
  • 使用具有抗菌特性的膠原蛋白黏合劑密封劑來減少術後感染

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 止血劑和組織密封劑市場（按產品類型）

  • 止血劑
    • 活性止血劑
    • 液體止血劑
    • 機械式止血鉗
  • 組織密封膠
    • 纖維蛋白膠
    • 合成密封膠

9. 止血劑和組織密封劑市場（按材料類型）

  • 天然材質
    • 牛為主
    • 以人為本
  • 合成材料
    • 膠原膠原蛋白
    • 聚合物基

10. 止血劑和組織密封劑市場（按應用）

  • 非手術治療
    • 診斷程序
    • 輕度傷口封閉
  • 外科手術
    • 心血管外科
    • 胃腸外科
    • 一般外科

第 11 章止血劑和組織密封劑市場（按最終用戶）

  • 門診手術中心
  • 診所
  • 醫院

12. 止血劑和組織密封劑市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 止血劑和組織密封劑市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國止血劑及組織密封劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Advanced Medical Solutions Group PLC
    • Aegis Lifesciences Private Limited.
    • B. Braun SE
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • Cardinal Health, Inc.
    • CooperSurgical, Inc.
    • CryoLife, Inc.
    • CSL Behring
    • CuraMedical BV
    • Grifols, SA
    • Hemostasis, LLC
    • Hologic, Inc.
    • Integra LifeSciences Corporation
    • Johnson & Johnson Services, Inc.
    • KAKEN PHARMACEUTICAL CO., LTD.
    • KATSAN Katgut Sanayi ve Tic. AS
    • Medline Industries, LP.
    • Medtronic PLC
    • Olympus Corporation
    • Owens & Minor
    • Pfizer, Inc.
    • Smith & Nephew PLC
    • Stryker Corporation
    • Teleflex Incorporated
    • Terumo Corporation
    • Thermo Fisher Scientific Inc.
    • Vivostat A/S
    • Zimmer Biomet
Product Code: MRR-437E9896A591

The Hemostats & Tissue Sealants Market is projected to grow by USD 17.80 billion at a CAGR of 12.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.85 billion
Estimated Year [2025] USD 7.69 billion
Forecast Year [2032] USD 17.80 billion
CAGR (%) 12.67%

A clear and authoritative introduction to the hemostats and tissue sealants environment explaining clinical, regulatory, and operational drivers shaping product adoption

The hemostats and tissue sealants arena has evolved into a high-impact segment at the intersection of surgical innovation, perioperative safety, and cost-aware health system management. Clinical teams are increasingly seeking adjunctive products that streamline hemostasis, reduce procedure times, and mitigate postoperative complications across a diverse array of specialties from cardiovascular and gastrointestinal surgery to general operative workflows. These clinical drivers are complemented by technological advances that expand product versatility and ease of use in both open and minimally invasive settings.

Concurrently, regulatory scrutiny and payer expectations are shaping how manufacturers prioritize evidence generation and value demonstration. That environment encourages multidisciplinary collaboration between R&D teams, clinical champions, and health economics experts to validate real-world outcomes beyond primary efficacy endpoints. As a result, product development now emphasizes not only hemostatic or sealing performance but also handling properties, storage stability, and compatibility with adjunctive devices and implants.

In this context, stakeholders must balance innovation with operational realities. Hospitals and ambulatory providers evaluate products for ease of adoption, staff training requirements, and supply chain reliability, while clinicians weigh the comparative clinical advantages in complex bleeding scenarios. This introductory framing establishes the subsequent discussion of structural shifts, tariff implications, segmentation insights, regional dynamics, competitive behaviors, and practical recommendations for industry leaders navigating the current landscape.

How surgical trends, materials innovation, and value-driven procurement are reshaping product development pathways and clinical adoption dynamics

The field of hemostats and tissue sealants is undergoing transformative shifts driven by converging trends in surgical practice, materials science, and health system economics. Minimally invasive and robotic procedures continue to expand into complex indications, increasing demand for formulations that perform reliably in restricted workspaces and under suction or irrigation conditions. Consequently, manufacturers are investing in next-generation flowable and active hemostat chemistries that enhance adhesion and clot stability while maintaining biocompatibility.

Material innovation is another pivotal axis of change. Advances in polymer engineering and biologics processing have enabled synthetic sealants that mimic fibrinous matrices while offering improved shelf life and standardized performance. These developments are accompanied by refinements in collagen-based scaffolds and composite constructs that target specific tissue interfaces, from vascular anastomoses to visceral serosal surfaces. The net effect is a broader product palette that can be tailored to surgeon preference and procedure-specific hemostatic challenges.

Market dynamics are also shifting as procurement approaches evolve. Health systems increasingly evaluate products within bundled care pathways and value-based contracting frameworks, prompting suppliers to generate evidence on metrics such as reduction in transfusion rates, decreased reoperation for bleeding, and shorter lengths of stay. Parallel to these commercial forces, digital health integration-ranging from inventory management analytics to intraoperative decision support-offers new avenues for differentiating product offerings and demonstrating measurable system-level benefits. Taken together, these transformative shifts are reshaping product roadmaps, clinical adoption trajectories, and competitive positioning across the ecosystem.

Assessing the multifaceted consequences of the 2025 United States tariff adjustments on supply chains, procurement strategies, and pricing dynamics

The tariff environment announced for 2025 in the United States introduces layered cost and operational implications for stakeholders across the hemostats and tissue sealants ecosystem. Manufacturers that rely on global sourcing of raw materials or maintain cross-border production footprints may face increased landed costs, which in turn pressure pricing strategies and margin structures. These pressures can incentivize nearshoring initiatives, contract renegotiations with suppliers, and reexamination of component standardization to mitigate tariff exposure.

Hospitals and ambulatory providers could experience indirect effects through supply chain volatility, with potential impacts on formularies and supplier consolidation strategies. In response, procurement teams may prioritize multi-source qualification, increased safety stock, and longer lead times for critical products. For smaller suppliers and emerging entrants, tariff-related cost increases may magnify barriers to scale, influencing partnership strategies and potentially accelerating mergers or distribution agreements with larger players that can absorb short-term cost fluctuations.

On the regulatory and reimbursement side, the tariff landscape intersects with broader cost-containment efforts, prompting manufacturers to make stronger value propositions based on clinical outcomes and total cost of care. Strategic responses to tariffs may include reformulation to incorporate domestically sourced inputs, reengineering packaging to reduce import duties, or pursuing deeper clinical evidence to support premium pricing where justified by demonstrable improvements in outcomes. Overall, the cumulative impact of the tariff changes will be mediated by each stakeholder's ability to adapt supply chain design, contracting practices, and evidence-based value communication.

Detailed segmentation insights linking product types, material classes, clinical applications, and end-user contexts to strategic commercialization imperatives

A nuanced understanding of segmentation is essential for tailoring product strategy and commercialization plans across distinct clinical and commercial submarkets. By product type, the landscape divides between hemostats and tissue sealants, with hemostats further differentiated into active hemostats, flowable hemostats, and mechanical hemostats and tissue sealants categorized into fibrin sealants and synthetic sealants. This product taxonomy affects how clinicians select adjuncts based on bleeding severity, anatomical access, and preferences for biologic versus engineered material performance.

Material type provides an orthogonal segmentation axis that influences sourcing, regulatory pathways, and perceived clinical risk. Natural materials encompass bovine-derived and human-derived options that carry considerations regarding donor variability, sterilization, and immunogenicity. Synthetic materials include collagen-based and polymer-based constructs that enable batch consistency and tailored degradation profiles but require rigorous biocompatibility validation to gain clinician trust.

Applications span non-surgical and surgical procedures, where non-surgical uses include diagnostic procedures and minor wound sealing and surgical applications encompass cardiovascular, gastrointestinal, and general surgery. The clinical context determines key product requirements such as adhesiveness under dynamic flow conditions, tensile strength at anastomoses, and compatibility with electrosurgical devices. Finally, end-user segmentation across ambulatory surgical centers, clinics, and hospitals informs distribution channel preferences, stocking practices, and purchasing authority, all of which must be considered when designing launch plans and post-market surveillance strategies.

How regional clinical practices, regulatory diversity, and manufacturing capacity dynamics shape differentiated strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics play a critical role in shaping research priorities, regulatory pathways, and commercial strategies for hemostats and tissue sealants. In the Americas, advanced healthcare infrastructure coupled with active surgical volumes creates strong clinical demand for both established biologic hemostats and innovative synthetic sealants. Stakeholders in this region often emphasize robust clinical evidence and integration into bundled care models, which influences how suppliers approach value articulation and reimbursement engagement.

Across Europe, the Middle East & Africa, heterogeneous regulatory regimes and variable procurement practices create a complex operating environment. European markets may favor products with strong comparative effectiveness data and established supply reliability, whereas emerging markets in the broader region prioritize cost-effectiveness and ease of distribution. This diversity necessitates flexible go-to-market strategies that respect local regulatory expectations while leveraging centralized clinical data for cross-border approvals.

The Asia-Pacific region exhibits rapid adoption of minimally invasive techniques and growing investment in domestic manufacturing capabilities. Local innovation ecosystems and evolving regulatory frameworks are increasingly supportive of clinical trials and commercialization of locally developed formulations. Consequently, suppliers that can demonstrate scalable manufacturing, localized regulatory strategies, and partnerships with regional clinical leaders are positioned to capture opportunities presented by rising surgical volumes and capacity expansion in the region.

Competitive and collaborative industry dynamics revealing how incumbent manufacturers, specialists, and innovators are shaping supply, evidence, and commercialization strategies

The competitive landscape is characterized by a mix of established surgical device manufacturers, specialized biologics firms, and nimble startups that emphasize material innovation or novel delivery formats. Legacy players leverage broad distribution networks, integrated sales forces, and longstanding hospital relationships to maintain presence across major specialties, while newer entrants frequently focus on single-indication differentiation or proprietary polymer chemistries that address unmet handling or performance gaps.

Partnerships and licensing agreements are common mechanisms for scaling distribution or integrating complementary technologies, enabling companies to combine clinical credibility with specialized manufacturing expertise. In parallel, contract manufacturing organizations and specialty material suppliers play decisive roles in ensuring quality, regulatory compliance, and capacity scalability, particularly for products with biologic inputs or complex polymer synthesis requirements.

Strategic priorities among firms include expanding indications through targeted clinical studies, optimizing product portfolios for minimally invasive platforms, and demonstrating health economic value that resonates with hospital procurement committees. Companies that align R&D investment with clear clinical endpoints and that can articulate system-level economic benefits will more effectively influence formulary decisions and surgical practice patterns.

Actionable recommendations for leaders to align clinical evidence, resilient supply chains, and value-driven commercial strategies for sustainable adoption

Industry leaders should adopt a multi-layered approach that aligns clinical development, supply chain resilience, and commercial engagement to secure durable adoption. First, investment in robust clinical evidence that links product performance to meaningful perioperative outcomes will be essential; pragmatic trials and real-world data collection should be integrated into launch and post-market plans to support adoption across diverse care settings.

Second, companies should reexamine supply chain architectures to mitigate tariff exposure and logistical disruptions. Strategies may include qualifying alternative raw material sources, pursuing localized manufacturing partnerships in key regions, and redesigning packaging to reduce cross-border duties. These measures should be complemented by transparent communication with procurement teams to build trust during periods of pricing and availability adjustments.

Third, commercialization should emphasize clinician training, clear handling guidance, and demonstration of compatibility with minimally invasive workflows and adjunctive devices. Tailored value propositions for ambulatory surgical centers, clinics, and hospitals will help address distinct purchasing behaviors and clinical workflows. Finally, proactive engagement with payers and health system value officers to present comprehensive outcome and cost narratives will support positioning in value-based care discussions and bundled payment arrangements.

A transparent, multi-method research methodology combining clinician insights, regulatory review, and supply chain analysis to inform strategic recommendations

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure a comprehensive and actionable perspective. Primary research involved structured interviews with clinical specialists across cardiovascular, gastrointestinal, and general surgery, as well as procurement leaders from hospitals, ambulatory surgical centers, and clinic settings. These discussions focused on real-world clinical performance, handling preferences, purchasing criteria, and adoption barriers for different hemostat and sealant categories.

Secondary analysis incorporated peer-reviewed clinical literature, regulatory guidance documents, product labeling, and manufacturing standards to validate material performance claims and regulatory pathways. Supply chain mapping and tariff impact assessment were conducted using trade flow analyses, input cost reviews, and consultation with industry procurement experts to identify likely operational implications and mitigation strategies.

Triangulation across data sources was used to corroborate findings and surface strategic implications. The methodological framework prioritized transparency in source attribution, reproducibility of analytic steps, and sensitivity to regional regulatory variance. Limitations and data gaps were identified to guide future research priorities and targeted primary data collection where necessary.

A concise conclusion synthesizing clinical imperatives, supply chain resilience, and strategic evidence needs that determine long-term adoption and value realization

In conclusion, the hemostats and tissue sealants sector stands at a strategic inflection point where clinical needs, material science advances, and economic pressures converge. Success in this environment requires an integrated strategy that pairs differentiated product performance with compelling evidence of downstream clinical and operational benefits. Stakeholders who invest in pragmatic clinical programs, resilient manufacturing and sourcing models, and targeted commercialization approaches will be best placed to influence adoption across heterogeneous care settings.

Tariff-driven cost dynamics and evolving procurement behaviors underscore the importance of agility in supply chain design and clarity in value communication. Meanwhile, regional opportunities vary in their regulatory expectations and infrastructure maturity, so localization of regulatory and commercialization approaches will remain a competitive advantage. Ultimately, the companies that can harmonize innovation with demonstrable hospital and patient-level outcomes will shape standards of care and capture the most sustainable opportunities in this evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of synthetic and hybrid polymer sealants in advanced surgical procedures
  • 5.2. Development of biologically derived hemostatic powders enriched with growth factors to enhance wound healing
  • 5.3. Expansion of minimally invasive robotic surgery driving demand for precision tissue sealants in laparoscopy
  • 5.4. Growing market preference for gelatin-based hemostats with enhanced biocompatibility and hemostasis efficacy
  • 5.5. Innovations in sprayable hemostatic agents allowing rapid application in trauma and emergency surgery settings
  • 5.6. Rising investment in point-of-care fibrinogen concentrates for targeted hemostasis in cardiovascular surgeries
  • 5.7. Adoption of collagen-based adhesive sealants combined with antimicrobial properties to reduce post surgical infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hemostats & Tissue Sealants Market, by Product Type

  • 8.1. Hemostats
    • 8.1.1. Active Hemostats
    • 8.1.2. Flowable Hemostats
    • 8.1.3. Mechanical Hemostats
  • 8.2. Tissue Sealants
    • 8.2.1. Fibrin Sealants
    • 8.2.2. Synthetic Sealants

9. Hemostats & Tissue Sealants Market, by Material Type

  • 9.1. Natural Materials
    • 9.1.1. Bovine-Derived
    • 9.1.2. Human-Derived
  • 9.2. Synthetic Materials
    • 9.2.1. Collagen-Based
    • 9.2.2. Polymer-Based

10. Hemostats & Tissue Sealants Market, by Application

  • 10.1. Non-Surgical Procedures
    • 10.1.1. Diagnostic Procedures
    • 10.1.2. Minor Wound Sealing
  • 10.2. Surgical Procedures
    • 10.2.1. Cardiovascular Surgery
    • 10.2.2. Gastrointestinal Surgery
    • 10.2.3. General Surgery

11. Hemostats & Tissue Sealants Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Hemostats & Tissue Sealants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hemostats & Tissue Sealants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hemostats & Tissue Sealants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Advanced Medical Solutions Group PLC
    • 15.3.3. Aegis Lifesciences Private Limited.
    • 15.3.4. B. Braun SE
    • 15.3.5. Baxter International Inc.
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Cardinal Health, Inc.
    • 15.3.8. CooperSurgical, Inc.
    • 15.3.9. CryoLife, Inc.
    • 15.3.10. CSL Behring
    • 15.3.11. CuraMedical B.V.
    • 15.3.12. Grifols, S.A.
    • 15.3.13. Hemostasis, LLC
    • 15.3.14. Hologic, Inc.
    • 15.3.15. Integra LifeSciences Corporation
    • 15.3.16. Johnson & Johnson Services, Inc.
    • 15.3.17. KAKEN PHARMACEUTICAL CO., LTD.
    • 15.3.18. KATSAN Katgut Sanayi ve Tic. A.S.
    • 15.3.19. Medline Industries, LP.
    • 15.3.20. Medtronic PLC
    • 15.3.21. Olympus Corporation
    • 15.3.22. Owens & Minor
    • 15.3.23. Pfizer, Inc.
    • 15.3.24. Smith & Nephew PLC
    • 15.3.25. Stryker Corporation
    • 15.3.26. Teleflex Incorporated
    • 15.3.27. Terumo Corporation
    • 15.3.28. Thermo Fisher Scientific Inc.
    • 15.3.29. Vivostat A/S
    • 15.3.30. Zimmer Biomet

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEMOSTATS & TISSUE SEALANTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEMOSTATS & TISSUE SEALANTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEMOSTATS & TISSUE SEALANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS